Boehringer Ingelheim boosts R&D commitment, promises up to 15 new product launches by 2025

Coming off a strong year of growth for its Eli Lilly-partnered SGLT2 inhibitor Jardiance, Boehringer Ingelheim is putting those gains right back into R&D — and setting some lofty goals for the next few years.